Whether the adverse prognosis resulted from subclonal evolution, such as the selection of clones with less immunogenicity [46], loss of MHC expression, or enhanced cell survival, could be revealed by collecting serial tumor biopsy specimens during and after therapy in future prospective studies and subjecting them to longitudinal NGS and flow cytometry experiments to monitor the clonal evolution. This evidence concerns the gene HLA-C and neoplasm.